Benefits
Standardized glucoraphanin delivery
Truebroc® standardizes to 13% glucoraphanin from broccoli seed — addressing the major issue with generic broccoli supplements (variable glucoraphanin content). Consistent labelled content is a manufacturing fact, not a health claim. No study cited here compared this branded extract against a generic broccoli extract, and how much sulforaphane you actually produce from it still depends on your own gut bacteria.
What the cited human studies actually measured
This is not accurate, so here is what the cited studies really found. None of them used Truebroc®, and none measured blood pressure or inflammatory markers. What was measured: dose-dependent increases in antioxidant enzymes in the human upper airway after an oral broccoli sprout preparation in a small placebo-controlled study (Riedl 2009); shifts in plasma metabolites linked to mitochondrial function after 12 weeks of eating high-glucoraphanin broccoli, which varied by genotype (Armah 2013); lower fasting glucose and HbA1c in a subgroup of obese people already diagnosed with type 2 diabetes (Axelsson 2017); and changes in urinary carcinogen-detoxification markers in 200 adults in Qidong, China (Kensler 2005).
Autism research does not apply to this product
No autism study appears anywhere in this page's reference list, so nothing here supports an autism claim. The published autism research on sulforaphane used broccoli sprout extracts and sulforaphane preparations, not Truebroc®, and autism is a medical diagnosis: no supplement should be presented as a treatment for it. Important note: subsequent autism trials have used different formulations including Avmacol® (Nutramax Laboratories), which combines broccoli seed and broccoli sprout blend with active myrosinase — not Truebroc® specifically. The autism evidence base supports the broader glucoraphanin/sulforaphane mechanism rather than Truebroc® as a specific product. For autism-specific applications, products with active myrosinase or pre-formed sulforaphane may be more relevant than Truebroc® alone.
NRF2 activation and detoxification enzyme upregulation
The enzyme data come from a small placebo-controlled dose-escalation study of an oral broccoli sprout preparation, not Truebroc®, which found dose-dependent increases in phase II enzymes (NQO1, GSTM1, GSTP1, HO-1) in the human upper airway (Riedl 2009). Detoxification was also genuinely measured in people: in a randomized trial in 200 adults in Qidong, China, an area with high dietary aflatoxin exposure, a broccoli sprout beverage raised urinary excretion of a phenanthrene detox metabolite, though there was no significant overall drop in aflatoxin-DNA adducts and the benefit depended on how well each person converted glucoraphanin to sulforaphane (Kensler 2005). These are laboratory markers of how the body handles specific chemicals in a high-exposure group. They are not evidence of a longer healthspan or of protection against any disease.
Standardization is a manufacturing claim
This is a manufacturing point, not evidence of a health benefit. Standardization tells you how much glucoraphanin is in the capsule. It does not tell you how much sulforaphane your body will make from it, and no study cited here compared this branded extract with a generic one.
Manufacturing consistency advantage
Truebroc® provides consistent glucoraphanin content from batch to batch, which is worth knowing when comparing products. But the autism and cardiovascular trials mentioned elsewhere on this page are not cited here and did not use this ingredient, so batch consistency should not be read as proof of those outcomes.
Mechanism of action
In-vivo sulforaphane generation
Truebroc® glucoraphanin reaches the intestine where gut bacteria with myrosinase activity (or supplemented myrosinase) convert it to bioactive sulforaphane. How much sulforaphane you end up with varies a lot between people, because it depends on your own gut bacteria. In the Qidong trial, the effect tracked with how well each person made that conversion. A glucoraphanin dose is therefore not the same as a sulforaphane dose.
NRF2 pathway activation
Sulforaphane activates the NRF2 pathway, which switches on antioxidant and detoxification enzymes. In people, a small trial of an oral broccoli sprout preparation raised several of these enzymes (NQO1, GSTM1, GSTP1, HO-1) in the upper airway. The often-quoted figures, such as dozens of enzymes for more than 24 hours, do not come from any study cited on this page.
Standardized bioavailability
No pharmacokinetic study of this branded extract is cited here, so there is no blood-level data on this page to back claims about reproducible plasma levels or predictable sulforaphane production.
Clinical trials
A 12-week randomized trial of a concentrated broccoli sprout extract, not Truebroc®, published in Science Translational Medicine (Axelsson 2017).
Clinical population described in trial publication.
Fasting glucose and HbA1c improved in a prespecified subgroup of obese patients with poorly controlled type 2 diabetes. The effect was modest, confined to that subgroup, the participants had a diagnosed disease and were under medical care, and the authors were connected to the company developing the extract. The metformin comparison in that paper was done in animals, not people. Nothing in it concerns blood pressure or inflammation, and it does not describe what this product does for a healthy person.
No autism trial is cited on this page. The published autism research used broccoli sprout extracts and sulforaphane preparations from other sources.
Clinical population described in trial publication.
No autism trial appears in this page's reference list, so there is no citation here to support an autism claim of any kind. The autism research usually mentioned alongside sulforaphane did not test Truebroc®, and later autism trials used Avmacol® (Nutramax), a different product that combines broccoli seed and sprout with active myrosinase. Autism is a medical diagnosis, and a dietary supplement should not be presented as a treatment for it.
A small placebo-controlled dose-escalation study of an oral broccoli sprout preparation, not Truebroc®.
Clinical population described in trial publication.
In a small placebo-controlled dose-escalation study, oral sulforaphane from a broccoli sprout preparation produced dose-dependent increases in phase II antioxidant enzymes (NQO1, GSTM1, GSTP1, HO-1) in the human upper airway (Riedl 2009). This is a gene-expression measurement in one tissue in a small group over a short period, not a health outcome, and the product tested was not Truebroc®.